Intellectual Property

SAJE started working in the S-nitrosoglutathione reductase (GSNOR) field in 2011 after acquiring from Indiana University an exclusive license to a patent application on GSNOR inhibiting technology. That patent has since issued in the US and the EPO and protects the use of SAJE’s first generation small molecule compound, SPL-334, and other structures for a number of inflammatory diseases including: asthma, COPD, IPF, cystic fibrosis, Crohn’s disease, and inflammatory bowel disease.

Since acquiring that first patent, SAJE has considerably strengthened its IP portfolio. The Company started its own chemistry discovery program at its laboratory at the University of Illinois Incubator in Chicago. To date, that program has discovered novel core structures that have been elaborated to produce numerous second and third generation GSNOR inhibitors that are novel compositions of matter with nanomolar IC50’s, potent therapeutic activity, oral, and hopefully, brain bioavailability.

On 26 February 2016, SAJE filed a patent application on its first novel core structure claiming composition of matter and therapeutic uses for many compounds derived from it. The structures were discovered from structure-activity relationships for the GSNOR active site and are proprietary to SAJE. The Company has X-ray crystallographic images of the enzyme with some of its inhibitors sitting in the active site. That information enables us to rationally design novel structures that block GSNOR activity. Three more patent applications in that series were filed in 2016.

SAJE is working with some of the best pharmaceutical patent attorneys in the United States to handle its IP. Those attorneys are from the patent firm of Shepard Mulin LLP in the San Francisco and Palo Alto, CA offices.

SAJE's IP Conclusion
Thus, SAJE believes that it has a robust and growing IP portfolio that has been and will be written to the highest standards in the industry by top pharmaceutical patent attorneys from a top IP firm, Foley and Lardner, and that that collective expertise will allow the company to move forward its disease programs, with a firm IP foundation underneath them.